Second, although we adjusted for aromatase inhibitor use (prevalence rate ranged from 9.36% to 14.08% in patients without and with a bone fracture) in our study, information on osteoporosis screening, bisphosphonate use, and compliance with concurrent guidelines for osteoporosis prevention was unavailable, which may bias our findings. The gene discussed is CYP19A1; the disease is osteoporosis.